7 unchanged sentences
A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at December 31, 2021 by approximately $0.6 million.
−Removed: We have an equity investment in the common stock of TELA Bio, which is publicly traded on the Nasdaq Global Select Market.
−Removed: TELA Bio is measured at fair value on a recurring basis.
−Removed: Changes in the price of its common stock will affect the value of our investment, and we could incur realized or unrealized losses on all or a part of the value of this investment.
−Removed: At December 31, 2020, the value of TELA Bio was $11.6 million, and a hypothetical 10% decrease in the market price would have caused a decrease in our carrying amount by $1.2 million.
−Removed: See Note 12, Financial Instruments , to our consolidated financial statements included herein for additional information on our equity investments.
−Removed: In July 2020, we issued $402.5 million in aggregate principal amount of our 2025 Notes, which mature in August 2025.
−Removed: Holders may convert their 2025 Notes prior to maturity under certain circumstances.
−Removed: Upon conversion, holders will receive the principal amount of the 2025 Notes and any excess conversion value in cash, shares of our common stock or a combination of cash and shares, at our option.
−Removed: The fair value of the 2025 Notes is impacted by both the fair value of our common stock and interest rate fluctuations.
−Removed: As of December 31, 2020, the estimated fair value of the 2025 Notes was $1,116 per $1,000 principal amount.
−Removed: See Note 11, Debt , to our consolidated financial statements included herein for further discussion of the 2025 Notes.
−Removed: The 2025 Notes bear interest at a fixed rate.
−Removed: At December 31, 2020, all $402.5 million of principal remains outstanding on the 2025 Notes.
−Removed: In March 2017, we issued $345.0 million in aggregate principal amount of our 2022 Notes, which mature in April 2022.
−Removed: In July 2020, we used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase $185.0 million aggregate principal of the 2022 Notes in privately-negotiated transactions for an aggregate of approximately $211.1 million in cash, including accrued interest.
−Removed: Holders may convert their 2022 Notes prior to maturity under certain circumstances.
−Removed: Upon conversion, holders will receive the principal amount of the 2022 Notes and any excess conversion value in cash, shares of our common stock or a combination of cash and shares, at our option.
−Removed: The fair value of the 2022 Notes is impacted by both the fair value of our common stock and interest rate fluctuations.
−Removed: The 2022 Notes bear interest at a fixed rate.
−Removed: As of December 31, 2020, the estimated fair value of the 2022 Notes was $1,144 per $1,000 principal amount.
−Removed: See Note 11, Debt , to our consolidated financial statements included herein for additional information on the 2022 Notes.
−Removed: At December 31, 2020, $160.0 million of principal remains outstanding on the 2022 Notes.
+Added: The fair values of our 2022 Notes and 2025 Notes are impacted by both the fair value of our common stock and interest rate fluctuations.
+Added: As of December 31, 2021, the estimated fair value of the 2025 Notes was $1,113 per $1,000 principal amount and the estimated fair value of the 2022 Notes was $1,039 per $1,000 principal amount.
+Added: See Note 11, Debt , to our consolidated financial statements included herein for further discussion of our 2022 Notes and 2025 Notes, which bear interest at fixed rates.
+Added: At December 31, 2021, all $402.5 million of principal remains outstanding on the 2025 Notes, and $160.0 million of principal remains outstanding on the 2022 Notes.
+Added: The Term Loan provided for a single-advance term loan in the principal amount of $375.0 million and is scheduled to mature on December 7, 2026.
+Added: Each term loan borrowing which is an alternate base rate borrowing bears interest at a variable rate per annum equal to the Alternate Base Rate (as defined in the Credit Agreement) subject to a 1.75% floor, plus 6.00%.
+Added: Each term loan borrowing which is a term benchmark borrowing bears interest at a variable rate per annum equal to (i) the Adjusted Term SOFR rate (as defined in the Credit Agreement) subject to a 0.75% floor plus (ii) 7.00%.
+Added: At December 31, 2021, we had $375.0 million in outstanding borrowings under the Term Loan.
+Added: A hypothetical 100 basis point increase in interest rates would have increased interest expense during the year ended December 31, 2021 by approximately $0.3 million, which considers that the Term Loan was outstanding for less than one month during 2021.
+Added: The impact of a hypothetical 100 basis point increase in interest rates would increase interest expense by $3.0 million in 2022.
+Added: As a result of the Flexion Acquisition and as discussed in more detail in Note 11, Debt , to our consolidated financial statements included herein, any future conversion rights for the Flexion 2024 Notes are subject to the occurrence of any future events giving rise to such conversion rights under the indenture governing the Flexion 2024 Notes.
We have agreements with certain vendors and partners that operate in foreign jurisdictions.
−Removed: The transactions under these agreements are primarily denominated in the U.S.
−Removed: Dollar, subject to periodic adjustment based on changes in currency exchange rates.
−Removed: Additionally, our accounts receivable are primarily concentrated with three large wholesalers of pharmaceutical products.
+Added: The more significant transactions are primarily denominated in the U.S.
+Added: Dollar, subject to an annual adjustment based on changes in currency exchange rates.
+Added: Additionally, our accounts receivable are primarily concentrated with four large wholesalers of pharmaceutical products.
In the event of non-performance or non-payment, there may be a material adverse impact on our financial condition, results of operations or net cash flow.
+Added: Financial Statements and Supplementary Data
+Added: Our consolidated financial statements required by this item, together with the report of our independent registered public accounting firm, begin on page F-1 of this Annual Report.
+Added: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.